Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy | Ophthalmology Times
A novel topical, incision-free therapy is now approved to help ophthalmologists slow or halt the progression of keratoconus. (Image credit: AdobeStock/Alessandro Grandini) Glaukos recently received FDA approval for its topical, incision-free therapy for keratoconus (Epioxa) that does not require removal…
Dompé’s NAION program selected for FDA Commissioner’s National Priority Voucher Program | Ophthalmology Times
(Image Credit: AdobeStock) Dompé was selected by the US Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of this selection, Dompé has received a voucher granting a significantly shortened review timeline for marketing…
Rethinking punctal occlusion as an option for allergic conjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock) The intracanalicular dexamethasone ophthalmic insert (Dextenza; Ocular Therapeutix) incorporates 0.4 mg of dexamethasone into the hydrogel matrix to treat postoperative inflammation and pain following ocular surgery. It is also approved for the treatment of ocular itching associated…
AAO 2025: Understanding and diagnosing endophthalmitis | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. At the 2025 annual meeting of the American Academy of Ophthalmology, Sunir J. Garg, MD, gave a presentation titled, “Endophthalmitis Sterile or not.” In an interview…
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. Diana Do, MD, a professor of ophthalmology and vice chair of Clinical Affairs at Stanford University’s Byers Eye Institute, presented research on aflibercept 8 mg in…
Stoke Therapeutics announces 2-year data from the natural history study, FALCON | Ophthalmology Times
(Image Credit: AdobeStock) Stoke Therapeutics announced 2-year data from the FALCON study, a prospective natural history study in people with autosomal dominant optic atrophy (ADOA). FALCON was a multicenter, 24-month, prospective natural history study of those aged 8 to 60…
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease | Ophthalmology Times
Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, highlighted findings from the STARLIGHT study at the American Academy of Ophthalmology 2025 annual meeting, held October 18-10, in Orlando, Florida. He focused on the use of MCO-010 optogenetic therapy…
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial | Ophthalmology Times
(Image Credit: AdobeStock/tonstock) Aurion Biotech has released positive 12-month results from its phase 1/2 CLARA trial evaluating the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. In the CLARA trial, a double-masked,…
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus | Ophthalmology Times
Glaukos’ FDA-approved Epioxa topical therapy offers a first-of-its-kind, incision-free treatment for patients with keratoconus, according to the company. Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for keratoconus.1,2 This approval…